BioSpace News Archive

China Oncology Focus, a subsidiary of Lee’s Pharm, has enrolled the first patient in the Socazolimab double-blinded Phase 3 study in combination with chemotherapy as a first-line treatment of extensive-stage small-cell lung cancer.

New efficacy and biomarker data to be featured in panel presentation on Wednesday, July 28.

Cell and gene therapies are niche ones and hence giant pharma firms are adding new products to existing product line, thereby enhancing manufacturing capacities.

GSK today announced it started shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2021-22 flu season

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. (“LyGenesis”), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they have discontinued negotiations for a merger agreement.

Jaguar Health, Inc. announced that effective July 15, 2021, the Company granted nonstatutory stock options for the purchase of up to 8,000 shares of the Company’s common stock to New Employee 1 and nonstatutory stock options for the purchase of up to 8,000 shares of the Company’s common stock to New Employee 2.

SQI Diagnostics Inc. (the “Company” or “SQI”) (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, announces that FDA will not continue its review of SQI’s submission of the RALI-Dx™ IL-6 Severity Triage Test for Emergency Use Authorization under the “Tests for Management of COVID-19 Patients” category.

The report highlights the trends prevailing in the global allergy treatment market, along with market drivers and deterrents.

The home sequential compression devices market was valued at US$ 992.49 million in 2021 and is projected to reach US$ 1,572.81 million by 2028; it is expected to grow at a CAGR of 6.8% from 2021 to 2028.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.